To access your BEI Web Portal Account:

Login 
    OR
Choose a Collection
OR
Choose an Organism
Back to My Search

Login is required to view Product Sheets and Certificates of Analysis.


Contact Us   Having technical issues or questions regarding this product?
Please Contact Us.
BEI Resources currently limits the total number of "Made to Order" items which can be ordered by a registrant to 10 "Made to Order" items per 6 month period. Please check the Availability Status on the items you are ordering and limit orders appropriately.
NR-431  Vaccinia virus Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-16), (produced in vitro)
(Monoclonal Antibodies)
Description: Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-16), (produced in vitro)
Organism: Vaccinia virus
Biosafety Level: 1
Availability Status: In Stock
Store at: -20°C or colder
Contributor: GH Cohen, RJ Eisenberg
Comments:
Quantity limit per order for this item is 5. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.

Mouse monoclonal antibody to a recombinant form of the B5R envelope glycoprotein [B5R(275t); residues 20 to 275 comprising the ectodomain, N-terminal histidine-tagged] of the Western Reserve (WR) strain of vaccinia virus was purified from a mouse B cell hybridoma using ammonium sulfate precipitation and size exclusion chromatography. The mouse B cell hybridoma was generated by the fusion of SP2/0 myeloma cells with immunized BALB/c splenocytes. NR-431 was purified from the same hybridoma as VMC-16. The specificity of VMC-16 was determined by reactivity to B5R(275t) by ELISA and confirmed by Western blot analysis under reducing and non-reducing conditions. The reactivity pattern in ELISA assays using overlapping peptides spanning residues 20 to 275 of B5R indicates that VMC-16 recognizes epitopes within amino acids 56 to 75 and 254 to 264. VMC-16 does not neutralize the infectivity of the extracellular enveloped virus (EEV) form of vaccinia virus in BS-C-1 cells using an EEV plaque reduction assay. VMC-16 does not inhibit the comet tail formation of the EEV form of vaccinia virus in BS-C-1 cells using a comet tail inhibition assay.

Each vial contains approximately 1.0 mL of purified monoclonal antibody in 50 mM borate buffer (pH 8.0 +/- 0.2) containing 0.1 M sodium chloride and no preservatives.
Citations: Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Monoclonal Anti-Vaccinia Virus (WR) B5R Protein, Residues 20 to 275 (Ectodomain), (similar to VMC-16), (produced in vitro), NR-431."
ATTACHMENTS
PERMITS
Select the country to see the list of permits that may be required for shipping this product.



Return to Top


Notices and Disclaimers

BEI Resources products are intended for laboratory research purposes only. They are not intended for use in humans.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this site, BEI Resources makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. BEI Resources does not warrant that such information has been confirmed to be accurate.


Back to My Search